Nautilus Biotechnology, Inc. (NASDAQ:NAUT) Q4 2023 Earnings Call Transcript
Nautilus Biotechnology, Inc. beats earnings expectations. Reported EPS is $0.14, expectations were $-0.16.
Nautilus Biotechnology Inc. (NAUT)
Market is closed
Hedge Fund Popularity
Hedge Fund Holdings
Filing Period:
Last updated on based on SEC 13F filings Last update:
| No. | Hedge Fund | Shares | Value | Activity | % Port |
|---|---|---|---|---|---|
| 1. | Perceptive Advisors Joseph Edelman | 12,594,211 | $37,656,690 | +39% | 0.84% |
| 2. | Cercano Management Chris Orndorff | 7,172,985 | $21,447,225 | 0.7% | |
| 3. | Alyeska Investment Group Anand Parekh | 441,018 | $1,318,644 | -2% | 0% |
| 4. | Clearline Capital Marc Majzner | 234,696 | $701,741 | -12% | 0.04% |
| 5. | Citadel Investment Group Ken Griffin | 114,918 | $343,605 | +1529% | 0% |
Insider Trading: Purchases See All
| Insider | Price | Amount | Relationship | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $2.84 | 12,044 | Large Shareholder, Officer, Director | 10,064,488 | 2024-03-11 | Filing | |
| $2.99 | 2,430 | Large Shareholder, Officer, Director | 10,052,444 | 2024-03-08 | Filing | |
| $2.89 | 18,854 | Large Shareholder, Officer, Director | 10,050,014 | 2024-03-07 | Filing | |
| $2.70 | 9,267 | Large Shareholder, Officer, Director | 10,031,160 | 2024-03-06 | Filing | |
| $2.65 | 7,405 | Large Shareholder, Officer, Director | 10,021,893 | 2024-03-05 | Filing |
Institutional Investors' Holdings
Filing Period:
| No. | Name | Shares | Value | % Port |
|---|---|---|---|---|
| 1. | 17,653,917 | $52,785,212 | 3.54% | |
| 2. | 3,893,637 | $11,641,976 | 0% | |
| 3. | 2,829,798 | $8,461,096 | 0% | |
| 4. | 2,207,619 | $6,600,781 | 0.23% | |
| 5. | 2,000,000 | $5,980,000 | 0.57% |
News See All
Nautilus Biotechnology, Inc. (NASDAQ:NAUT) Q3 2023 Earnings Call Transcript
Operator: Thank you for standing by, and welcome to the Nautilus Third Quarter 2023 Earnings Conference Call. At this time, all participants are in a listen-only mode.
Nautilus Biotechnology, Inc. (NASDAQ:NAUT) Q2 2023 Earnings Call Transcript
Operator: Thank you for standing by, and welcome to the Nautilus Biotechnology Second Quarter 2023 Earnings Conference Call. [Operator Instructions] As a reminder, today's program is being recorded.
Nautilus Biotechnology, Inc. (NASDAQ:NAUT) Q1 2023 Earnings Call Transcript
Operator: Good morning and thank you for standing by. Welcome to the Nautilus First Quarter 2023 Earnings Conference Call.
Jeff Bezos Stock Portfolio: 10 Companies and Startups
If there's one thing that can be said for sure, it's that Jeff Bezos knows how to follow his gut. Amazon.com, Inc.
Nautilus Biotechnology, Inc. (NASDAQ:NAUT) Q4 2022 Earnings Call Transcript
Operator: Good day, and thank you for standing by. Welcome to the Nautilus Biotechnology Q4 and Full Year 2022 earnings conference call. Please be advised that today's conference is being recorded.
Nautilus Biotechnology Inc (NAUT): Hedge Funds Are Coming Back
Many prominent investors, including Warren Buffett, David Tepper and Stan Druckenmiller, have been cautious regarding the current bull market and missed out as the stock market reached another high in...
Jeff Bezos Stock Portfolio: 5 Companies Bezos Is Investing In
In this article, we discuss the 5 companies Bezos is investing in.
11 Biotech Stocks Popular On Reddit
Biotechnology is one of the fields in which Reddit investors take active interest amid an explosive growth potential of the biotech industry.
10 Best Medical Stocks Under $10
While the COVID-19 virus spread worldwide, the medical industry proved its resilience and capacity to bring life-saving products to market promptly.
Billionaire Hedge Funds
